伦瓦提尼
医学
彭布罗利珠单抗
内科学
耐火材料（行星科学）
肿瘤科
甲状腺癌
放射性碘疗法
甲状腺
癌症研究
癌症
免疫疗法
生物
天体生物学
作者
Jena D. French,Bryan R. Haugen,Francis P. Worden,Daniel W. Bowles,Andrew G. Gianoukakis,Bhavana Konda,Ramona Dadu,Eric J. Sherman,Shaylene McCue,Nathan R. Foster,Yuri E. Nikiforov,Ticiana D.J. Farias,Paul J. Norman,Lori J. Wirth
标识
DOI：10.1158/1078-0432.ccr-23-3417
摘要
Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
bc
昏睡的蟠桃
剑指东方是为谁
yufanhui
赫枫
高大凌寒
机灵柚子
平常的毛豆
Thien
余味
冰魂
非而者厚
andrele
pcr163
VDC
核桃
遇上就这样吧
SYLH
飘零无边
皖公网安备34019202002308
